Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.57 |
| ▸ | HDAC1 known ✓ | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.51 |
| ▸ | ROCK2 known ✓ | O75116 | 1/20 | 0.46 |
| ▸ | ROCK1 known ✓ | Q13464 | 1/20 | 0.46 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.45 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.45 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.62 |
| ▸ | F7 | P08709 | 1/20 | 0.60 |
| ▸ | F3 | P13726 | 1/20 | 0.60 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.60 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.60 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.60 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.60 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.60 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.60 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30113106 | 1.00 | PLOD2 (0.62) | PLOD2F7F3SARM1SIRT2 | |
| Hydrochloric Acid SCHEMBL5419648 | 1.00 | PLOD2 (0.62) | PLOD2F7F3SARM1SIRT2 | |
| SCHEMBL2296114 | 0.98 | PLOD2 (0.65) | PLOD2F7F3SARM1SIRT2 | |
| SCHEMBL29786297 | 0.98 | PLOD2 (0.65) | PLOD2F7F3SARM1SIRT2 | |
| Urea SCHEMBL15552231 | 0.96 | F7 (0.61) | PLOD2F7F3SARM1SIRT2 | |
| Trifluoroacetic Acid SCHEMBL4883046 | 0.87 | PLOD2 (0.63) | PLOD2F7F3SARM1SIRT2 | |
| SCHEMBL21133737 | 0.85 | PLOD2 (0.62) | PLOD2F7F3SARM1SIRT2 | |
| Hydrochloric Acid SCHEMBL9490379 | 0.82 | HDAC1 (0.61) | PLOD2F7F3SARM1SIRT2 | |
| Hydrochloric Acid SCHEMBL31026319 | 0.82 | HDAC1 (0.61) | PLOD2F7F3SARM1SIRT2 | |
| SCHEMBL10320930 | 0.82 | PLOD2 (0.89) | PLOD2F7F3SARM1SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | disclosed |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | THE BROAD INSTITUTE, INC. | 2023-10-12 | — | — | US | disclosed |
| EP-4188551-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-20150197503-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL PORTELA & Cª S A (PT) | 2015-07-16 | — | — | US | disclosed |
| EP-2882712-A2 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - Portela & Cª S.A. (PT) | 2015-06-17 | — | — | EP | disclosed |
| WO-2014017938-A2 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2014-01-30 | — | — | WO | disclosed |
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | HONGU MITSUYA | 2010-10-07 | — | — | US | disclosed |
| US-7759373-B2 | Large conductance calcium-activated K channel opener | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-20 | — | — | US | disclosed |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| WO-2002083111-A2 | IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE | TANABE SEIYAKU CO., LTD. (JP) | 2002-10-24 | — | — | WO | disclosed |
| EP-0369743-B1 | Heterocyclic amides | ZENECA LTD (GB) | 1995-04-19 | — | — | EP | disclosed |
| US-5324723-A | Analgesics | MERCK SHARPE & DOHME LTD. | 1994-06-28 | — | — | US | disclosed |
| EP-0543245-A1 | Renin inhibiting amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1993-05-26 | — | — | EP | disclosed |
| EP-0307141-B1 | OXAZOLES AND THIAZOLES FOR THE TREATMENT OF SENILE DEMENTIA | MERCK SHARP & DOHME LTD. (GB) | 1993-01-13 | — | — | EP | disclosed |
| EP-0506729-A1 | PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS | Beecham Group p.l.c. (GB) | 1992-10-07 | — | — | EP | disclosed |
| US-5091425-A | Inhibitors of the catalytic action of renin | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-02-25 | — | — | US | disclosed |
| WO-1991009856-A1 | PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS | BEECHAM GROUP PLC (GB) | 1991-07-11 | — | — | WO | disclosed |
| EP-0369743-A2 | Heterocyclic amides | ZENECA LIMITED (GB) | 1990-05-23 | — | — | EP | disclosed |
| EP-0307141-A2 | Oxazoles and thiazoles for the treatment of senile dementia | MERCK SHARP & DOHME LTD. (GB) | 1989-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256165-A1 | LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER | KCNN3, KCNN2, KCNN1 | GAA 4627/4885HDAC1 1133/4885HDAC6 1559/4885 |
| US-20080103170-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNG, CHRNE, CHRNA1 | GAA 2272/4885HDAC1 2107/4885HDAC6 2114/4885 |
| US-20070249588-A1 | Nicotinic Acetylcholine Receptor Ligands | CHRNA1, CHRNB1, CHRNA2 | GAA 3879/4885HDAC1 1364/4885HDAC6 1738/4885 |
| US-20150197503-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | REN, F12, HAT1 | GAA 1915/4885HDAC1 98/4885HDAC6 396/4885 |
| US-20230322767-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | PNPO, THPO, PAH | GAA 207/4885HDAC1 1974/4885HDAC6 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.